Free Trial

CG Oncology (CGON) Competitors

CG Oncology logo
$36.70 -0.34 (-0.92%)
Closing price 04:00 PM Eastern
Extended Trading
$36.68 -0.02 (-0.04%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CGON vs. QGEN, BBIO, ROIV, ELAN, MRNA, VRNA, RVMD, RGC, GRFS, and RYTM

Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Qiagen (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Regencell Bioscience (RGC), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

CG Oncology vs. Its Competitors

CG Oncology (NASDAQ:CGON) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

QIAGEN has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$1.14M2,454.71-$88.04M-$1.77-20.73
QIAGEN$1.98B5.12$83.59M$1.6926.98

CG Oncology has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

CG Oncology presently has a consensus price target of $56.00, indicating a potential upside of 52.59%. QIAGEN has a consensus price target of $49.69, indicating a potential upside of 8.95%. Given CG Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe CG Oncology is more favorable than QIAGEN.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92
QIAGEN
0 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.27

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 70.0% of QIAGEN shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

QIAGEN has a net margin of 18.30% compared to CG Oncology's net margin of -15,945.17%. QIAGEN's return on equity of 14.77% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-15,945.17% -19.37% -18.72%
QIAGEN 18.30%14.77%8.87%

In the previous week, CG Oncology had 11 more articles in the media than QIAGEN. MarketBeat recorded 18 mentions for CG Oncology and 7 mentions for QIAGEN. QIAGEN's average media sentiment score of 0.91 beat CG Oncology's score of 0.53 indicating that QIAGEN is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CG Oncology
8 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
QIAGEN
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

QIAGEN beats CG Oncology on 10 of the 17 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGON vs. The Competition

MetricCG OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.82B$3.17B$5.77B$10.52B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-20.7321.0476.4326.62
Price / Sales2,454.71407.35534.76119.62
Price / CashN/A46.3537.4661.85
Price / Book3.819.7813.616.45
Net Income-$88.04M-$52.73M$3.29B$271.57M
7 Day Performance2.63%2.40%1.67%2.83%
1 Month Performance36.33%4.69%4.05%7.27%
1 Year Performance-4.28%16.28%80.70%26.07%

CG Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGON
CG Oncology
2.5415 of 5 stars
$36.70
-0.9%
$56.00
+52.6%
-5.0%$2.82B$1.14M-20.7361Insider Trade
Gap Up
QGEN
Qiagen
4.3617 of 5 stars
$45.39
+0.2%
$49.69
+9.5%
+4.7%$10.07B$2.04B26.825,765
BBIO
BridgeBio Pharma
4.4974 of 5 stars
$51.47
+0.5%
$63.94
+24.2%
+92.7%$9.79B$235.81M-12.58400
ROIV
Roivant Sciences
3.4223 of 5 stars
$13.95
-0.9%
$17.67
+26.6%
+24.8%$9.61B$29.05M-19.93860Trending News
Insider Trade
Analyst Revision
ELAN
Elanco Animal Health
2.5844 of 5 stars
$18.63
+0.5%
$17.33
-6.9%
+35.6%$9.21B$4.48B21.669,000
MRNA
Moderna
4.4611 of 5 stars
$23.88
+1.6%
$41.81
+75.1%
-59.6%$9.15B$3.06B-3.175,800Trending News
VRNA
Verona Pharma PLC American Depositary Share
2.0358 of 5 stars
$106.37
-0.1%
$109.00
+2.5%
+254.3%$8.71B$221.67M-107.4430Positive News
RVMD
Revolution Medicines
4.2884 of 5 stars
$46.20
-0.8%
$73.67
+59.5%
-2.2%$8.70BN/A-10.27250
RGC
Regencell Bioscience
0.1406 of 5 stars
$14.35
-2.4%
N/AN/A$7.27BN/A0.0010Gap Up
GRFS
Grifols
3.9109 of 5 stars
$9.63
-2.5%
$10.30
+7.0%
+8.4%$6.79B$7.81B8.2323,822
RYTM
Rhythm Pharmaceuticals
3.2028 of 5 stars
$96.03
-0.2%
$101.57
+5.8%
+87.5%$6.39B$156.29M-31.90140Positive News

Related Companies and Tools


This page (NASDAQ:CGON) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners